Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Raises FY 2013 EPS Guidance; Reaffirms FY 2013 Revenue Guidance


Thursday, 25 Apr 2013 07:29am EDT 

Celgene Corp announced that for fiscal 2013, it raises adjusted diluted EPS guidance to a range of $5.55 to $5.65 from a range of $5.50 to $5.60 and total net product sales guidance is affirmed to $6.0 billion. GAAP diluted EPS expected to be in the range of $4.32 to $4.47 which includes upfront payment expense for alliances and collaborations. 

Company Quote

113.35
3.75 +3.42%
26 Dec 2014